and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.
Participating Organization(s) |
National Institutes of Health (NIH) |
National Institute of Allergy and Infectious Diseases (NIAID) |
|
Funding Opportunity Title |
Chemical Approaches to Target Validation for Drug Resistant Pathogens (R01) |
Activity Code |
R01 Research Project Grant |
Announcement Type |
New |
Related Notices |
None |
Funding Opportunity Announcement (FOA) Number |
RFA-AI-11-004 |
Companion FOA |
None |
Catalog of Federal Domestic
Assistance (CFDA) Number(s) |
93.855; 93.856 |
FOA Purpose |
The purpose of this FOA is to solicit research focused on using chemical tools to either address scientific questions about microbial biological processes and host-pathogen interactions and/or determine the biological activity of host or pathogen proteins. Rather than focusing on identifying medicinal products, these teams will take a broader approach of analyzing biological targets that can serve as the basis for future chemical screens to identify drug candidates as well as contribute to functional annotation of gene products. |
Posted Date |
February 17, 2011 |
Open Date (Earliest Submission Date) |
April 13, 2011 |
Letter of Intent Due Date |
May 13, 2011 |
Application Due Date(s) |
June 15, 2011, by 5:00 PM local time of applicant organization. |
AIDS Application Due Date(s) |
Not Applicable |
Scientific Merit Review |
|
Advisory Council Review |
|
Earliest Start Date(s) |
March, 2012 |
Expiration Date |
June 16, 2011 |
Due Dates for E.O. 12372 |
Not Applicable |
Required Application Instructions
It is critical that applicants follow the instructions in the SF 424 (R&R) Application Guide except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission
Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
Purpose
The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) supports extramural research focused on understanding, controlling and preventing human disease caused by human infectious agents. Through the increase in drug resistance in clinically relevant pathogens (e.g. those for which drug resistance has been documented and new anti-infective agents are critically needed), there is an urgent need to define physiological pathways in pathogens and complementary pathways in the host and to define relevant, and chemically validated biological targets for use in developing treatments for infectious diseases.
Through this FOA, the NIAID invites applications for research focused on using chemical tools to either address scientific questions about microbial biological processes and host-pathogen interactions and/or determine the biological activity of host or pathogen proteins. Rather than focusing on identifying medicinal products, a broader approach of analyzing biological targets that can serve as the basis for future chemical screens to identify drug candidates as well as contribute to functional annotation of gene products should be taken.
At the end of the project period, a successful project will either contribute substantial data to the characterization of a biological drug target (in vitro and/or in vivo) or will have contributed to the functional annotation of pathogen genes and pathways. Projects must assess the potential of a target to be inhibited by a chemical entity. This inhibition should result in decreased or abolished viability of the pathogen in vitro (microbial viability) and/or in vivo (lack of growth or establishment of pathology in animal models). It is expected that projects will also contribute to the functional annotation of gene products and biochemical signaling pathways relevant to infectious disease.
Collaborations
A key component of this initiative is the establishment of collaborative teams of chemists and biologists with demonstrated expertise in their respective discipline, who will use chemical approaches to address scientific questions about microbial biological processes and host-pathogen interaction. For this FOA, cross-disciplinary collaborations are required.
Background
Diseases for which there is only limited interest from pharmaceutical partners for drug development suffer from the lack of applied scientific evaluation that is needed to create industry-quality drug targets. Currently, the study of biological targets by academia is primarily focused on knock-out mutagenesis while approaches for genetic or functional down-regulation of enzymatic or protein activity are only beginning to emerge. The definition of an "essential target is often inferred from the fact that its elimination results in non-viability. However, targets may exist whose function, when compromised by chemical entities, leads to reduced or abolished growth in vivo. The publication of extensive genomic and proteomic data has enabled the creation of physiological maps whose key intervention points lend themselves to further study. Using chemical approaches to study physiological processes rather than relying on the complete removal of key enzymes through knock-out mutagenesis has the potential to identify appropriate interventional targets and offers the opportunity to create more rational approaches to drug discovery.
NIAID has offered many targeted funding initiatives over the years to create drug development partnerships between academia and industry. Some of these efforts have resulted in promising chemical candidates that have advanced to the clinical stage. The NIH Molecular Roadmap initiative (http://nihroadmap.nih.gov/molecularlibraries/ ), as well as several individual NIAID contracts and NIAID's preclinical services (http://www.niaid.nih.gov/labsandresources/resources/Pages/default.aspx ), have enabled the identification of small molecule hits from large library screens against biological targets. These have resulted in a significant number of valuable chemical entities that are publically accessible (http://pubchem.ncbi.nlm.nih.gov/, http://mli.nih.gov/mli/mlp-probes/) and can be evaluated for their potential to serve as small molecule chemical tools for the characterization of new biological targets and the eventual development of novel antimicrobial agents. Conversely, biologically active small molecule chemical entities identified through whole cell screening efforts have the potential to identify potentially novel biological targets.
For the purpose of this FOA, small molecule chemical tools are defined as small molecules that bind reversibly or irreversibly to a protein(s) or other biological macromolecules and in doing so induce a biochemical response that can be measured directly (biochemical assay) or indirectly (cellular or functional response). Small molecule chemical tools should be suitable for use in biological experiments that will allow an understanding of a biological target’s role in infectious disease sufficient to suggest the target as a candidate for drug discovery screening (i.e. biological target validation). General considerations for selection of small molecule chemical tools are summarized in Workman and Collins, Chemistry & Biology 17, June 25, 2010, p 561 ff.
Research Goals and Objectives
The objectives of this FOA are:
This FOA focuses on the use of existing small molecule chemical tools, related structures and relevant negative control chemicals, to study pathogen "physiology" so that biochemical pathways can be targeted that will interfere with the pathogen's capacity to induce disease.
Small molecule chemical tool(s) may be used to characterize biological targets in vivo and in vitro or characterize physiological pathways in microbes and thus add to the body of knowledge of microbial metabolic processes contributing to growth and virulence. Chemical modification of existing molecules including synthesis of analogs may be included but will only be supported to a limited degree such as may be required to integrate functional labels for detection, imaging and/or isolation of target bio-molecules.
A strong justification for the selection of targets and pathways as well as the quality, identity and suitability of the small molecule chemical tool for the intended purpose must be presented in the application. The minimum data provided in the application to support this justification should be in accordance with the summaries required by Nature Chemical Biology to report on in vitro, cellular and in vivo information for newly reported or newly characterized small molecule chemical tools (www.nature.com/nchembio/chemical_probes.html).
All projects must focus on human relevant pathogens (excluding HIV) for which drug resistance has been documented or new anti-infectives are needed. Applications may include non-resistant-strains or model organisms where studies with the pathogenic organism are not feasible. A strong, appropriate and clear justification for the applicability of the results to a human pathogen must be provided. Non-responsive applications will not be reviewed.
Applicants are required to include project performance and timeline objectives as a component of the research strategy. Applications lacking the Milestones and Timeline section will be deemed non-responsive and will not be reviewed. This section should be limited to 1 page and must include:
NOTE: This FOA will NOT support drug development or screening for new drug hits or leads.
Funding Instrument |
Grant |
Application Types Allowed |
New The OER Glossary and the SF 424 (R&R) Application Guide provide details on these application types. |
Funds Available and Anticipated Number of Awards |
The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious applications. NIAID intends to fund an estimate of range 10-12 awards, corresponding to a total of $8,000,000 for fiscal year 2012. Future year amounts will depend on annual appropriations. |
Award Budget |
Application budgets need to reflect the actual needs of the proposed project and are limited to $750,000 direct costs in any year of the award. |
Award Project Period |
Scope of the proposed project should determine the project period. The maximum period is 5 years.. |
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Higher Education Institutions:
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
For profit Organizations
Governments
Other
Foreign (non-U.S.) components of U.S. Organizations are allowed.
Applicant organizations must complete the following registrations
as described in the SF 424 (R&R) Application Guide to be eligible to apply
for or receive an award. Applicants must have a valid Dun and Bradstreet
Universal Numbering System (DUNS) number in order to begin each of the following
registrations.
All Program Directors/Principal Investigators (PD/PIs) must
also work with their institutional officials to register with the eRA Commons
or ensure their existing eRA Commons account is affiliated with the eRA Commons
account of the applicant organization.
All registrations must be completed by the application due date. Applicant
organizations are strongly encouraged to start the registration process at
least four (4) weeks prior to the application due date.
Any individual(s) with the skills, knowledge, and resources
necessary to carry out the proposed research as the Project Director/Principal
Investigator (PD/PI) is invited to work with his/her organization to develop an
application for support. Individuals from underrepresented racial and ethnic
groups as well as individuals with disabilities are always encouraged to apply
for NIH support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple
Program Director/Principal Investigator Policy and submission details in the Senior/Key
Person Profile (Expanded) Component of the SF 424 (R&R) Application Guide.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
NIH will not accept any application in response to this FOA that is essentially the same as one currently pending initial peer review unless the applicant withdraws the pending application. NIH will not accept any application that is essentially the same as one already reviewed.
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the Apply for Grant Electronically button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
Descriptive title of proposed research
Name, address, and telephone number of the PD(s)/PI(s)
Names of other key personnel
Participating institutions
Number and title of this funding opportunity
The letter of intent should be sent to:
Yong Gao, Ph.D.
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
6700-B Rockledge Drive
Room 3246, MSC-7616
Bethesda, MD 20892-7616 (Express courier zip: 20817-7616)
Telephone: (301) 443-8115
FAX: 301-480-2408
Email: gaol2@niaid.nih.gov
The forms package associated with this FOA includes all applicable components, mandatory and optional. Please note that some components marked optional in the application package are required for application submission. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate optional components.
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Resource Sharing Plan
Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS) as provided in the SF424 (R&R Application Guide), with the following modifications:
Appendix
Do not use the appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
Foreign (non-US) organizations must follow policies described in the NIH Grants Policy Statement, and procedures for foreign organizations described throughout the SF424 (R&R) Application Guide.
Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit in advance of the deadline to ensure they have time to make any application corrections that might be necessary for successful submission.
Organizations must submit applications via Grants.gov, the online portal to find and apply for grants across all Federal agencies. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration.
Applicants are responsible for viewing their application in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF 424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.
Important
reminders:
All PD/PIs must include their eRA Commons ID in the Credential
field of the Senior/Key Person Profile Component of the SF 424(R&R) Application
Package. Failure to register in the Commons and to include a valid PD/PI
Commons ID in the credential field will prevent the successful submission of an
electronic application to NIH.
The applicant organization must ensure that the DUNS number it provides on the
application is the same number used in the organization’s profile in the eRA
Commons and for the Central Contractor Registration (CCR). Additional
information may be found in the SF424 (R&R) Application Guide.
See more
tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review and responsiveness by NIAID, NIH. Applications that are incomplete and/or nonresponsive will not be reviewed.
Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-10-115.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
The objectives of this R01 grant program are to support projects that propose a broad approach to analyzing biological targets that can serve as the basis for future chemical screens to identify drug candidates as well as contribute to functional annotation of gene products. At the end of the project period, a successful project will either contribute substantial data to the characterization of a biological drug target (in vitro and/or in vivo) or will have contributed to the functional annotation of pathogen genes and pathways..
Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Significance
Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Is this project likely to establish proof-of-concept for a novel target or biological process? If the aims of the application are achieved, is it likely that a validated biological target will emerge or that significant insight into biological pathways will be gained? Are sufficient data on the small molecular chemical tool provided to demonstrate that it is appropriate for the intended studies? Did the applicant provide appropriate justification for choice of pathogens targeted in the application?
Investigator(s)
Are the PD/PIs, collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project? Does the application propose the appropriate combination of qualified investigators from relevant disciplines to form the cross-disciplinary collaborations as required in the FOA?
Innovation
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed? Are the proposed multi-disciplinary collaborations using existing small molecule chemical tools in a novel way to validate biologically relevant targets or pathways? Does the approach represent an innovative use of novel and emerging technologies and appropriate collaborations to achieve the research objectives?
Approach
Are the overall strategy, methodology, and analyses
well-reasoned and appropriate to accomplish the specific aims of the project?
Are potential problems, alternative strategies, and benchmarks for success
presented? If the project is in the early stages of development, will the
strategy establish feasibility and will particularly risky aspects be
managed?
If the project involves clinical research, are the plans for 1) protection of
human subjects from research risks, and 2) inclusion of minorities and members
of both sexes/genders, as well as the inclusion of children, justified in terms
of the scientific goals and research strategy proposed?
Do they propose appropriate collaborations that will meet the goals of the FOA?
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact/priority score, but will not give separate scores for these items.
Milestones
Did the applicant submit concise research milestones and timelines that adequately address the specific research areas described in the FOA? Are the milestones and timeline appropriate and feasible?
Protections for Human Subjects
For research that involves human subjects but does
not involve one of the six categories of research that are exempt under 45 CFR
Part 46, the committee will evaluate the justification for involvement of human
subjects and the proposed protections from research risk relating to their
participation according to the following five review criteria: 1) risk to
subjects, 2) adequacy of protection against risks, 3) potential benefits to the
subjects and others, 4) importance of the knowledge to be gained, and 5) data
and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or
more of the six categories of research that are exempt under 45 CFR Part 46,
the committee will evaluate: 1) the justification for the exemption, 2) human
subjects involvement and characteristics, and 3) sources of materials. For
additional information on review of the Human Subjects section, please refer to
the Human
Subjects Protection and Inclusion Guidelines.
Inclusion of Women, Minorities, and Children
When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the Human Subjects Protection and Inclusion Guidelines.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Resubmissions
Not Applicable
Renewals
Not Applicable
Revisions
Not Applicable
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact/priority score.
Applications from Foreign Organizations
Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the National Institute of Allergy and Infectious Diseases (assignments will be shown in the eRA Commons), in accordance with NIH peer review policy and procedures, using the stated review criteria.
As part of the scientific peer review, all applications:
Applications will be assigned to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA . Following initial peer review, recommended applications will receive a second level of review by the National Advisory Allergy and Infectious Diseases Council l. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH
will request "just-in-time" information from the applicant as
described in the NIH Grants
Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided
to the applicant organization for successful applications. The NoA signed by
the grants management officer is the authorizing document and will be sent via
email to the grantee business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection
of an application for award is not an authorization to begin performance. Any
costs incurred before receipt of the NoA are at the recipient's risk. These
costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to the DUNS,
CCR Registration, and Transparency Act requirements as noted on the Award
Conditions and Information for NIH Grants website.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Cooperative Agreement Terms and Conditions of Award
Not Applicable.
When multiple years are involved, awardees will be required to submit the Non-Competing Continuation Grant Progress Report (PHS 2590) annually and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and Financial Status Report are required when an award is relinquished when a recipient changes institutions or when an award is terminated.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
Grants.gov
Customer Support (Questions regarding Grants.gov registration and
submission, downloading or navigating forms)
Contact Center Phone: 800-518-4726
Email: support@grants.gov
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
Telephone 301-710-0267
TTY 301-451-5936
Email: GrantsInfo@nih.gov
eRA Commons Help Desk(Questions regarding eRA Commons
registration, tracking application status, post submission issues)
Phone: 301-402-7469 or 866-504-9552 (Toll Free)
TTY: 301-451-5939
Email: commons@od.nih.gov
Dr. Christine Sizemore
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-435-2857
Email:cs390s@nih.gov
Yong Gao, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-443-8115
Email: gaol2@niaid.nih.gov
Victoria Connors
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-402-5065
Email: connorsv@mail.nih.gov
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |
||||||